<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510012</url>
  </required_header>
  <id_info>
    <org_study_id>nCOV19</org_study_id>
    <nct_id>NCT04510012</nct_id>
  </id_info>
  <brief_title>Characterizing the Immune Response and Neuronal Damage in COVID-19</brief_title>
  <official_title>Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators plan to study the innate and adaptive immune response, the inflammatory
      response, and associated complications such as complement activation and neurological damage
      in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease
      will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to
      severe illness requiring mechanical ventilation. Immunological factors which lead to severe
      disease in certain COVID-19 patients remain incompletely understood. Neurological damage and
      complement activation may be a consequence of excess inflammation in severe COVID-19. The
      investigators plan to study the innate and adaptive immune response and potentially
      associated complications such as neurological damage and complement activation in mild,
      moderate and severe COVID-19 courses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">March 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine response to SARS-Cov-2</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine response to SARS-Cov-2</measure>
    <time_frame>28 days (+/-7) after enrollment</time_frame>
    <description>Measurement of cytokine concentration (pg/ml) in serum (IL-6, IL-8, IL-1b,TNF-alpha)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Innate immune response to SARS-Cov-2</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measurement of HLA-DR expression on CD14+ cells (flowcytometry)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Innate immune response to SARS-Cov-2</measure>
    <time_frame>3 days after enrollment</time_frame>
    <description>Measurement of HLA-DR expression on CD14+ cells (flowcytometry)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Innate immune response to SARS-Cov-2</measure>
    <time_frame>5 days after enrollment</time_frame>
    <description>Measurement of HLA-DR expression on CD14+ cells (flowcytometry)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Humoral immune response</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measurement of neutralizing SARS-Cov-2 antibody concentrations (plaque reduction assay)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell mediated immune response</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell mediated immune response</measure>
    <time_frame>28 days (+/-7) after enrollment</time_frame>
    <description>Measurement of frequencies of SARS-Cov-2 specific T-cells (ELISPOT assay)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological damage</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological damage</measure>
    <time_frame>28 days (+/-7) after enrollment</time_frame>
    <description>Measurement of neurofilament light chains in serum (on ELLA platform; Protein Simple, Bio-techne)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complement activation</measure>
    <time_frame>At enrollment</time_frame>
    <description>Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement activation</measure>
    <time_frame>28 days (+/-7) after enrollment</time_frame>
    <description>Measurement of factor B, factor H, factor I, C3a, C4a, C5a, SC5b9</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Mild COVID-19</arm_group_label>
    <description>SARS-Cov-2 infected individuals with mild symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 1-2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate COVID-19</arm_group_label>
    <description>SARS-Cov-2 infected individuals with moderate symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 3-4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe COVID-19</arm_group_label>
    <description>SARS-Cov-2 infected individuals with severe symptoms (WHO Ordinal Scale for Clinical Improvement in COVID-19: scores 5-8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.</intervention_name>
    <description>Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.</description>
    <arm_group_label>Mild COVID-19</arm_group_label>
    <arm_group_label>Moderate COVID-19</arm_group_label>
    <arm_group_label>Severe COVID-19</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma, Peripheral Blood Mononuclear Cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (≤ 18 years) patients with PCR confirmed SARS-Cov-2 infection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCR confirmed SARS-Cov-2 infection

        Exclusion Criteria:

          -  Refusal to participate

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cédric Hirzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leib L Stephen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Infectious Diseases; Bern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jörg C Schefold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cédric Hirzel, MD</last_name>
    <phone>+41316640117</phone>
    <email>cedric.hirzel@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Hirzel, MD</last_name>
      <phone>+41316640117</phone>
      <email>cedric.hirzel@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Ronald Dijkman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaud Spinetti, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franziska Suter, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Grandgirard, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Innate immune response</keyword>
  <keyword>Adaptive immune response</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Neurological damage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement System Proteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

